Tipp

Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients

Zeitschrift:: Wiener Medizinische Wochenschrift > Ausgabe 15-16/2013

Autoren:: MD Katherine Boyd, MD Sofia M Shea, MD James Patterson

Summary

Survival of solid organ transplant patients has been prolonged, leading to increased incidence of non-melanoma skin cancers. Metastatic squamous cell carcinoma is an increasing problem in these patients. This paper reviews the evidence available for the treatment of advanced squamous cell carcinoma with the epidermal growth factor receptor inhibitor, cetuximab.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Jensen P, Hansen S, Moller B, Leivestad T, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–86. PubMedCrossRef

Ritchie SA, Patel MJ Miller SJ. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg. 2012;38:1604–21. PubMedCrossRef

Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342–6. PubMed

Martinez JC, Otley CC, Okuno SH, Foote RL, Kasperbauer JL. Chemotherapy in the setting of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg. 2004;30:679–86. PubMedCrossRef

Ch’ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol. 2008;39:344–9. PubMedCrossRef

Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010;15:1320–8. PubMedCrossRef

Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quereux G, Dreno B. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2013;1–4 (Epub ahead of print).

Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010;28:8–14. PubMedCrossRef

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. PubMedCrossRef

Maubec E, Petrow P, Duvillard P, et al. Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study (abstract). J Clin Oncol. 2010;28:8510.

Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257–61. PubMedCrossRef

Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007;143:889–92. PubMedCrossRef

Suen JK, Bressler L, Hord SS, et al. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007;18:827–92. PubMedCrossRef

Wollina U. Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther. 2012 Jul;12(7):949–56. PubMedCrossRef

Giacchero D, Barriere J, Benezery K, Guillot B, Dutriaux C, Mortier L, Lacour J-P, Thuss A, Peyrade F. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma—a report of eight cases. Clin Oncol. 2011;23:716–21. CrossRef

Mecca C, Ponzetti A, Caliendo V, Ciuffreda L, Lista P. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol. 2012;22(6):758–61. PubMed

Vaccaro M, Barbuzza O, Pollicino A, Guarneri C. Acneiform eruption following molecular targeted chemotherapy. Intern Med J. 2011 Apr;41(4):361–2. PubMedCrossRef

Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Durgs Today 2005;41(2)107–27. CrossRef

Valeriani M, Muni R, Osti MF, De Sanctis V, Minniti G, Ardito F, Maurizi Enrici R. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy. Radio Med. 2012;117:125–32. CrossRef

Bonner JA, Harai PM, Girait J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78. PubMedCrossRef

Mydin AR, Armstrong JG. Radiotherapy plus cetuximab is safe in a head and neck cancer patient on immunosuppressants for liver transplant. J Clin Oncol 2007 Feb;365–6.

Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, Hoopes CW. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26:1340–4. PubMedCrossRef

Titel: Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients
Autoren:: MD Katherine Boyd
MD Sofia M Shea
MD James Patterson
Publikationsdatum: 01.08.2013
DOI: https://doi.org/10.1007/s10354-013-0213-5
Verlag: Springer Vienna
Zeitschrift: Wiener Medizinische Wochenschrift
Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2013

Advanced basal cell carcinoma

Nachruf Prof. Dr. Walter H. Hörl 11.7.1945 – 25.6.2013

Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach

Atypical fibroxanthoma—a diagnosis of exclusion!

Cutaneous side effects of vemurafenib: a case report and discussion

Merkelzellkarzinom: eine Überprüfung und Aktualisierung über die Pathogenese, Diagnose und Therapieansätze